



# ADVANCES IN THERAPY OF MULTIPLE MYELOMA



September 30, 2012  
Heidelberg, Germany

**Brian GM Durie, MD**  
**Cedars-Sinai, Los Angeles**




*Improving Lives • Finding the Cure*



Dedicated to improving the quality of life of myeloma patients while working towards prevention and a cure




# MANAGING MYELOMA THE COMPONENTS OF CARE





# INCREASING NUMBER OF NEW DRUGS






# IMPROVING OVERALL SURVIVAL IN MYELOMA

## Impact Of Transplant And Novel Therapies

Overall survival 1971–2006



Diagnosis period      Median OS

Last decade            45 months

Before last decade    30 months

$p < 0.001$

50% improvement

...further increase  
for 2007-2012

Kumar SK, et al. Blood. 2008;111:2516-20



# TREATMENT SEQUENCE


**NEW**

Thal/Dex  
Rev/Dex  
Cyclo/vel/dex  
VD  
RevVel  
VTD

SCT  
VD/VRD  
MPT?  
VMP?

Nothing  
Thalidomide?  
Bortezomib?  
Lenalidomide?

Bortezomib  
Lenalidomide  
Thalidomide  
*Carfilzomib*  
*Pomalidamide*  
*Elotuzumab*  
HDAC  
*Bendamustine*



**OLD**

VAD  
DEX

SCT


Nothing  
Prednisone  
Thalidomide

Few options



# YOU NEED GOOD COMBINATIONS

## WHICH ONES ARE BEST?





# WHAT'S BEST IN 2012?

## 2 DRUG

Rd: LENALIDOMIDE/DEX

VD: BORTEZOMIB/DEX

KD: CARFILZOMIB/DEX

CD: CYCLOPHOSPHAMIDE/DEX

## 3 DRUG

VRd

VCd

KCd

CTD or VTD

“PAD”



# INDIVIDUALIZING CARE

## Important Factors


- Age
  - High Risk cytogenetics
  - Renal disease
    - Convenience/location
    - Blood counts
    - Steroid “status”
    - Previous therapy

and PATIENT PREFERENCE





# PUTTING TOGETHER NEW COMBOS



Dedicated to improving the quality of life of myeloma patients while working towards prevention and a cure



# ADDING IN A NEW DRUG

## New Drug Trial Example

ELOTUZUMAB/LENALIDOMIDE/DEX

ELOQUENT 1 @ [clinicaltrials.gov- NCTO1335399](https://clinicaltrials.gov/ct2/show/study/NCT01335399)

### Randomized Study

- Len/dex ± Elotuzumab
- Previously untreated myeloma
- Non-ASCT candidates



# ISSUES WITH CURRENT OPTIONS

1. Toxicity
2. Convenience
3. Cost
4. Ability to collect stem cells
5. Long term risks (?)

## KEY POINT

Does DEPTH of response predict  
DURATION of response?



# KEY DECISION FACTORS

## SITUATION

1. Renal impairment
2. Convenience
3. Cytopenias
4. Neuropathy
5. High risk disease

## CHOICE

- Bortezomib
- Lenalidomide
- Bortezomib or thal
- Lenalidomide
- Bortezomib



## NEXT QUESTION

**Will cure come from**

**....an extra piece for the puzzle?**

**or**

**....something different entirely?**



# KEY ROLE OF IMWG

## Moving Research Forward

### Chairs:


- Brian G.M. Durie
- S. Vincent Rajkumar
- Antonio Palumbo
- Jésus San-Miguel
- Philippe Moreau

### 3<sup>rd</sup> Annual IMWG Summit Key Questions 2012

Sofitel Hotel

Oudezijds Voorburgwal 197  
NL-1012 EX Amsterdam

June 11-13, 2012



Dedicated to improving the quality of life of myeloma patients while working towards prevention and a cure



# INAUGURAL IMWG SUMMIT



**Barcelona  
2010**



**London  
2011**



**Amsterdam  
2012**

Dedicated to improving the quality of life of myeloma patients while working towards prevention and a cure



# IMWG PAPERS ON THE IMF WEBSITE



INTERNATIONAL MYELOMA FOUNDATION

*Improving the quality of life of myeloma patients while working toward prevention and a cure*

 SEARCH ▾

Need help?  
Click to Talk

Contact Us

We are international



-select-



Donate

- about myeloma
- research
- health professionals
- support
- webcasts
- meetings
- advocacy
- fundraising
- media
- blogs
- about IMF



clinical trials

- myeloma working group
- global clinical trials forum
- nurse leadership board
- seminars & meetings
- kyle lifetime achievement award
- webcasts
- comprehensive guides
- bank on a cure®
- nurse leadership board
- oh, nurse! the nlb blog
- nlb teleconferences
- nlb consensus guidelines

## International Myeloma Working Group (IMWG)

TEXT SIZE - +

### COLLABORATION AND CONSENSUS IN THE SEARCH FOR A CURE



IMF's International Myeloma Working Group consists of 150 leading myeloma researchers from around the world who collaborate on a broad range of myeloma research projects. With a goal to improve myeloma treatment options and diagnostic systems, their work focuses on protocols to provide a more durable remission for myeloma patients while improving quality of life, addressing the needs of both myeloma patients and the physicians who treat them.

Watch a short video about the IMWG

### Mission of the IMWG IMWG Publications IMWG Guidelines

To conduct basic, clinical and translational research in a collaborative manner to improve outcomes in myeloma, and to provide scientifically valid and critically appraised consensus opinions on the diagnosis and treatment of myeloma and related disorders.

In further pursuit of this mission, IMWG holds an [annual summit](#) to identify, support, and implement the most promising research to prevent onset of active disease, improve treatment, and find a cure for myeloma.

The IMWG has a two-fold task: to conduct translational research—from lab bench to patient bedside—under the auspices of the IMF and to publish consensus statements and guidelines for the management of myeloma. These publications represent both the work of the IMWG and the work of individual IMWG members who have based their papers on IMWG data sets that were made available to them.

[MORE >>](#)

These guidelines from the International Myeloma Working Group (IMWG) represent a capsule summary, capturing the main points of, but not intended to replace the publications from which they came.

As with all guidelines, they are informational and may contain issues to be discussed with your treating physician.

To see the full list, click on "view all" in the bottom right hand corner.

[MORE >>](#)

We thank our website sponsors

[Amgen](#) [Binding Site](#) [Celgene Corporation](#) [Onyx Pharmaceuticals](#)

We welcome our international partners [Canada](#) [China](#) [Czech Republic](#) [Europe](#) [Israel](#) [Italy](#) [Japan](#) [Latin America](#)

Dedicated to improving the quality of life of myeloma patients while working towards prevention and a cure





# IMWG: RECENT PUBLICATIONS

## MAINTENANCE

- Ludwig, Attal, IMWG consensus on maintenance therapy in multiple myeloma BLOOD (Impact Factor- 9.8)

## TRANSPLANT

- Cavo, Lonial, International Myeloma Working Group (IMWG) consensus statement on the treatment of multiple myeloma patients who are candidates for autologous stem-cell transplantation BLOOD (Impact Factor- 9.8)

## RELAPSE

- Kumar, S. et al 'Risk of Progression and Survival in Multiple Myeloma Relapsing After Therapy with IMiDs and Bortezomib: A Multicenter International Myeloma Working Group Study' Leukemia (Impact Factor- 9.5)


## NEUROPATHY

- Richardson, "IMWG Recommendations on the Management of Treatment-Emergent Peripheral Neuropathy in Multiple Myeloma" Leukemia (Impact Factor- 9.5)



# MODEL OF MYELOMA OVER TIME


EARLY ← → RELAPSE



FEWER ← → **MULTIPLE CLONES** → MORE  
CURATIVE Rx ← → SALVAGE Rx



# PROGRESS TOWARDS A CURE



Dedicated to improving the quality of life of myeloma patients while working towards prevention and a cure

